Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient l-amino acid-defined diet

Biochemical and Biophysical Research Communications

Volumn 364, Issue 4, 2007, Pages 801-807

  Jin, Haiyan ^a,b   Yamamoto, Naoki ^a   Uchida, Koichi ^a   Terai, Shuji ^a   Sakaida, Isao ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YANBIAN UNIVERSITY   (China)

Author keywords

Angiotensin II type 1 receptor antagonist; Fibrosis; Hepatic stellate cell(s); Nonalcoholic steatohepatitis

Indexed keywords

AMINO ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CHOLINE; COLLAGENASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; TELMISARTAN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; DIETARY INTAKE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; RAT; STELLATE CELL; VITAMIN DEFICIENCY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BENZIMIDAZOLES; BENZOATES; CHOLINE DEFICIENCY; DOSE-RESPONSE RELATIONSHIP, DRUG; L-AMINO ACID OXIDASE; LIVER CIRRHOSIS; MALE; RATS; RATS, WISTAR; TREATMENT OUTCOME;

RATTUS;

EID: 36148979351     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.10.083     Document Type: Article

References (23)

1. Fassio E., Alvarez E., Domínguez N., Landeira G., and Longo C. Natural history of nonalcholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40 (2004) 820-826
2. Ratziu V., Bonyhay L., Di Martino V., Charlotte F., Cavallaro L., Sayegh-Tainturier M.H., Giral P., Grimaldi A., Opolon P., and Poynard T. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35 (2002) 1485-1493
3. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., and McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999) 1413-1419
4. Bataller R., Gäbele E., Parsons C.J., Morris T., Yang L., Schoonhoven R., Brenner D.A., and Rippe R.A. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 41 (2005) 1046-1055
5. Paizis G., Cooper M.E., Schembri J.M., Tikellis C., Burrell L.M., and Angus P.W. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 123 (2002) 1667-1676
6. Bataller R., Gines P., Nicolas J.M., Görbig M.N., Garcia-Ramallo E., Gasull X., Bosch J., Arroyo V., and Rodes J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118 (2000) 1149-1156
7. Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Noguchi R., Nakatani T., Tsujinoue H., and Fukui H. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34 (2001) 745-750
8. Bataller R., Sancho-Bru P., Gines P., Lora J.M., Al-Garawi A., Sole M., Colmenero J., Nicolas J.M., Jimenez W., Weich N., Gutierrez-Ramos J.C., Arroyo V., and Rodes J. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 125 (2003) 117-125
9. Friedman S.L. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N. Engl. J. Med. 328 (1993) 1828-1835
10. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., Forlani G., and Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 107 (1999) 450-455
11. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., Qi N., Wang J., Avery M.A., and Kurtz T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR gamma-modulating activity. Hypertension 43 (2004) 993-1002
12. Nanji A.A. Animal models of nonalcoholic fatty liver disease and steatohepatitis. Clin. Liver Dis. 8 (2004) 559-574
13. Sakaida I., Kubota M., Kayano K., Takenaka K., Mori K., and Okita K. Prevention of fibrosis reduces enzyme-altered lesions in the rat liver. Carcinogenesis 15 (1994) 2201-2206
14. Jin H., Sakaida I., Tsuchiya M., and Okita K. Herbal medicine Rhei rhizome prevents liver fibrosis in rat liver cirrhosis induced by a choline-deficient l-amino acid-defined diet. Life Sci. 76 (2005) 2805-2816
15. Jin H., Terai S., and Sakaida I. The iron chelator deferoxamine causes activated hepatic stellate cells to become quiescent and to undergo apoptosis. J. Gastroenterol. 42 (2007) 475-484
16. Nakae D. Endogenous liver carcinogenesis in the rat. Pathol. Int. 49 (1999) 1028-1042
17. Matsuoka M., and Tsukamoto H. Stimulation of hepatic lipocyte collagen prodiction by Kupffer cell-derived transforming growth factor beta: implication for a pathogenetic role in alcoholic liver fibrogenesis. Hepatology 11 (1990) 599-605
18. Benyon R.C., Hovell C.J., Da Gaça M., Jones E.H., Iredale J.P., and Arthur M.J. Progelatinase A is produced and activated by rat hepatic stellate cells and promotes their proliferation. Hepatology 30 (1999) 977-986
19. Kossakowska A.E., Edwards D.R., Lee S.S., Urbanski L.S., Stabbler A.L., Zhang C.L., Phillips B.W., Zhang Y., and Urbanski S.J. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am. J. Pathol. 153 (1998) 1895-1902
20. Hazra S., Xiong S., Wang J., Rippe R.A., Krishna V., Chatterjee K., and Tsukamoto H. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J. Biol. Chem. 279 (2004) 11392-11401
21. Benyon R.C., Iredale J.P., Goddard S., Winwood P.J., and Arthur M.J. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 110 (1996) 821-831
22. Rosen E.D., and Spiegelman B.M. PPAR gamma: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276 (2001) 37731-37734
23. Picard F., and Auwerx J. PPAR (gamma) and glucose homeostasis. Annu. Rev. Nutr. 22 (2002) 167-197